Treatment of inflammatory bowel disease with IFN-γ inhibitors
AssigneeGenentech, Inc.
InventorsAvi J. Ashkenazi, Rebecca H. R. Ward
Life of this patent
Estimating the term…
Abstract
The invention concerns a method for the prevention or treatment of inflammatory bowel disease by administering an interferon-γ inhibitor. The invention further concerns pharmaceutical compositions and bispecific molecules useful in such method.
Claims25
A method for treatment of ulcerative colitis or Crohn's disease in a patient comprising administering to the patient an effective amount of an interferon gamma (IFN-γ) inhibitor selected from the group consisting of an IFN-γ receptor, an anti-IFN-γ antibody, and an anti-IFN-γ receptor antibody, wherein the IFN-γ inhibitor inhibits the binding of native IFN-γ to its native receptor.
A method for treatment of ulcerative colitis or Crohn's disease in a patient comprising administering to the patient an effective amount of an interferon gamma (IFN-γ) inhibitor selected from the group consisting of an IFN-γ receptor, an anti-IFN-γ antibody, and an anti-IFN-γ receptor antibody, and a TNFα inhibitor selected from the group consisting of an anti-TNFα antibody, an anti-TNFα receptor antibody, and a TNFα receptor immunoadhesin, wherein the IFN-γ inhibitor inhibits the binding of native IFN-γ to its native receptor, and wherein the TNFα inhibitor inhibits the binding of native TNFα to its native receptor.
Dependencies are inferred from the claim text.